ibrutinib,rituximab,bendamustine
roche,janssen,abbvie,biogen,teva pharmaceuticals
['ibru', 'lymsm', 'shine', 'lymphoma']
congress #eha22 | presented phase iii shine study of ibrutinib+br in older pts with mcl. n=523. median follow-up=84.7 months, median pfs=80.6 months, orr=89.7% #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm